In May of 2023, the Centers for Medicare & Medicaid Services (CMS) proposed to upend more than three decades of historical precedent by rewriting the rules of the road for Medicaid drug rebate calculations. This sweeping rule fundamentally shifts the reimbursement structure of drugs, placing a substantial burden on manufacturers and putting patient access at risk. This session will shed light on the current healthcare landscape one year after the rule was initially proposed and the industry’s ongoing efforts to mitigate the rule’s negative impacts. Provisions that will be covered include the best price stacking proposal, the new definition of covered outpatient drug, the drug price verification survey, and other patient access considerations.